BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $21.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2019-02-25
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for the quarter ending 2011-03-31 was $21.00M.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2018 was $21.00M, a 59.62% decline from fiscal 2017.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2017 was $52.00M, a 0.00% change from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2016 was $52.00M, a 18.18% increase from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2015 was $44.00M, a 47.62% decline from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|---|
| 2018-12-31 | $21.00M 10-K · filed 2019-02-25 | |
| 2017-12-31 | $52.00M 10-K · filed 2019-02-25 | |
| 2016-12-31 | $52.00M 10-K · filed 2019-02-25 | |
| 2015-12-31 | $44.00M 10-K · filed 2018-02-13 | |
| 2014-12-31 | $84.00M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $63.00M 10-K · filed 2016-02-12 | |
| 2012-12-31 | $90.00M 10-K · filed 2015-02-13 | |
| 2011-12-31 | $80.00M 10-K · filed 2014-02-14 | |
| 2011-03-31 | $21.00M 10-Q · filed 2011-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |